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Abstract
Biospecimen donation is key to the Precision Medicine Initiative, which pioneers a model for accelerating biomedical research
through individualized care. Personalized medicine should be made available to medically underserved populations, including
the large and growing US Hispanic population. We present results of a study of 140 Hispanic women who underwent a breast
biopsy at a safety-net hospital and were randomly assigned to receive information and request for consent for biospecimen and
data sharing by the patient’s physician or a research assistant. Consent rates were high (97.1% and 92.9% in the physician and re-
search assistant arms, respectively) and not different between groups (relative risk [RR] ¼ 1.05, 95% confidence interval [CI] ¼
0.96 to 1.10). Consistent with a small but growing literature, we show that perceptions of Hispanics’ unwillingness to participate
in biospecimen sharing for research are not supported by data. Safety-net clinics and hospitals offer untapped possibilities for
enhancing participation of underserved populations in the exciting Precision Medicine Initiative.
On January 20, 2015, President Obama announced the Precision
Medicine Initiative (PMI), a bold new research effort that has the
potential to revolutionize how we treat disease, including can-
cer. Although this initiative promises to result in great scientific
advances, questions remain as to how members from diverse
communities in the United States will become involved and
benefit from discoveries resulting from the PMI. Without ade-
quate racial/ethnic representation, the PMI has the potential to
exacerbate cancer disparities, as higher-resource individuals
benefit more from adoption of technological advances than
those from low-income groups (1).
The participation of racial/ethnic and low-income popula-
tions in biospecimen sharing is vital to the success of the PMI.
Published reports show that there is under-representation of
racial/ethnic groups, including Hispanics, in biobanks (2,3).
Hispanics comprise a growing population in the United States
that is largely absent from public data sets, such as The Cancer
Genome Atlas (TCGA; <3%). Furthermore, Hispanics make up
4% of participants included in the National Cancer Institute’s
Cancer Epidemiology Cohort infrastructure program (4).
Although some data exist on Hispanics’ willingness to donate
biospecimens for research (3,5,6), less is known about actual
provision of these specimens, and no data exist on methods of
consent. Here we report results of a study among Hispanic
women who were randomly assigned to receive information
and request for consent for biospecimen donation by either: 1)
patient’s physician or 2) a research assistant who was not part
of the health care team. We hypothesized that consent rates
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would be higher in the physician arm than the research assis-
tant arm.
Eligible women were age 18 years or older, of Hispanic eth-
nicity, English- or Spanish-speaking, and had undergone a
breast biopsy at Maricopa Medical Center, a safety-net hospital
in Phoenix, Arizona. Consent for biospecimens included provi-
sion of formalin-fixed paraffin-embedded tissue from the prior
biopsy and a saliva sample (for DNA) collected at the time of
consent. Study recruitment involved a two-step process. First,
the provider asked the patient about her interest in participat-
ing in the trial. If she agreed, she was randomly assigned to be
consented by the provider or the research assistant. Using an
electronic tablet, the consent was shown to the patient and was
also explained verbally by the consenter. All patients were given
additional time to read and review the information on the tablet
and provided the opportunity to ask questions prior to signing.
Eighty-five percent (119/140) of women were consented in
Spanish. The consent covered future research (including genetic
studies) and noted that biospecimens could be kept indefinitely,
utilized to develop commercial products, or shared with re-
search collaborators without reconsent. Data collection in-
cluded sociodemographic variables, risk factor information, and
health literacy (7). We recruited 140 patients (70 to each arm)
(see Supplementary Figure 1, available online), which was esti-
mated to give 85% power to detect a difference of 20% or more
between the two groups. The relative risk (RR) and 95% confi-
dence interval (CI) were estimated comparing the proportion of
individuals consenting to biospecimen collection between the
two arms. The study was approved by the Institutional Review
Board at Maricopa Medical Center. All statistical tests were two-
sided, and a P value of less than .05 was considered statistically
significant.
Participant characteristics reflect those of a safety-net hospi-
tal serving primarily a Southwest Hispanic population: a high
percentage of Mexican-descent and Spanish-speaking women,
low education and income levels, and a high proportion with
limited health literacy (Table 1). Consent rates for biospecimen
and data sharing were high in both arms: 97.1% in the
physician-delivery arm and 92.9% in the research assistant–
delivery arm, with no statistically significant difference (RR ¼
1.05, 95% CI ¼ 0.96 to 1.10, P ¼ .25, calculated using Pearson’s
chi-squared test) (Table 2).
Results of our study show high rates of consent for biospeci-
men and data sharing among low-income, un/underinsured
Hispanic women, regardless of whether the request for consent
was delivered by their physician or a nonmember of the health
care team. Having a nonphysician obtain consent addresses the
possible concerns that conflation of research participation and
clinical evaluation may drive biospecimen donation (5).
Reported reasons for lower participation of Hispanics in bio-
specimen sharing include limited English proficiency, limited
health literacy, or cultural norms (6,8), as well as immigration
status among foreign-born individuals (9). Our results suggest
that health literacy is not a factor given the high rates of partici-
pation in spite of limited health literacy (85%). While an argu-
ment can be made that racial/ethnic minorities constitute
“hard-to-reach populations,” emerging data on Hispanics sug-
gest that this ethnic community is willing to and does share bio-
specimens for research purposes (3,6–8). Further, Loffredo et al.
showed that trust was not an issue in willingness to donate bio-
specimens among foreign-born Hispanics (6).
Our findings have direct implications to the efforts of the
PMI, where biological samples will be queried for genetic varia-
tions and could contribute to diminishing racial/ethnic dispar-
ities in cancer outcomes. However, without access to biological
samples that are representative of the diversity in the United
States, this will not be possible, as is the case in TCGA. Our high
rates of consent for biospecimen sharing are consistent with
published data on Hispanics, which include provision of biospe-
cimens among residents in rural areas (10), willingness to do-
nate biospecimens among foreign-born inner-city individuals
(6), and data on Mexican Americans from the National Health
and Nutrition Examination Survey (11).
Limitations of our study include the select patient population
of Hispanic women, primarily of Mexican descent from a single in-
stitution, limiting generalizability. Although consent rates were
high when not obtained by the patient’s physician, suggesting that
conflation of research participation and clinical evaluation did not
influence the high rates, we cannot fully exclude this possibility.
The continued racial/ethnic shift in the US population is proj-
ected to result in a majority-minority distribution by 2043 (12).
However, to date, there is marked under-representation of racial/
ethnic minority groups in clinical trials (13,14) and biospecimen
banks (2,3). To address this inequity, an understanding of how to
best include and engage individuals from under-represented
groups, including Hispanics, will be required. We propose that
this ethnic group’s unwillingness to donate biospecimens is a
myth not supported by data. Unlike other racial/ethnic groups,
most Hispanics do not have a marked history of mistrust of the
medical community. Partnerships among academic institutions,
safety-net clinics, and hospitals offer potential for enhancing
participation of diverse racial/ethnic groups and underserved in-
dividuals, which will be important for PMI efforts. These partner-
ships will ensure that medically underserved populations benefit
from the exciting discoveries that are yet to come from precision
Table 1. Patient characteristics by random assignment arm
Characteristic
Physician Research assistant
(n¼ 70) (n¼ 70)
Age, mean 6 SD, y 47.0 6 13.1 46.4 6 10.0
Hispanic subgroup, No. (%)
Mexican 66 (94.3) 67 (95.7)
Other 4 (5.7) 3 (4.3)
Education, y, mean 6 SD 8.9 6 4.2 8.6 6 4.1
Income, $/mo, mean 6 SD 1034.7 6 718.4 1046.3 6 682.8
Health insurance, No. (%)
None 54 (77.1) 59 (84.3)
Medicaid 14 (20.0) 8 (11.4)
Medicare/private 2 (2.9) 3 (4.3)
Spanish-speaking, No. (%) 56 (80) 63 (90)
Limited health literacy, No. (%) 59 (84.3) 54 (77.1)
Cancer diagnosis, No. (%) 21 (30.0) 13 (18.6)
Table 2. Informed consent for biospecimen and data sharing among
participants randomly assigned to consent delivered by their physi-
cian vs a research assistant
Random assignment arm
Positive consent
RR (95% CI) P*No. (%)
Research assistant 65/70 (92.9) 1.00 (Ref)
Physician 68/70 (97.1) 1.05 (0.96 to 1.10) .25
*Two-sided Pearson’s chi-squared test was used to calculate the P value. CI ¼
confidence interval; RR ¼ relative risk.
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medicine and help prevent false discoveries that result from
sampling from a homogeneous population (15).
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